Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV^Ⓡ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study.

ABSTRACT:

Objectives

Typhoid infections remain one of the major health concerns worldwide. Vaccines that prevent typhoid, particularly, the conjugated polysaccharide ones, are an important tool in addressing this major health concern. Here, we report on the safety profile of Biological E's TYPHIBEV^Ⓡ when administered to infants, children, and young adults and immunogenic non-interference data of TYPHIBEV when co-administered with the measles rubella (MR) vaccine to infants.

Methods

This phase IV multicenter, open-label study enrolled 1252 healthy subjects aged 6 months to 45 years, stratified into three age subsets. In the 6 months to 2 years age group, 400 subjects aged 9-12 months were randomly allocated 1:1 to receive TYPHIBEV^Ⓡ and MR vaccine or MR vaccine onl

SUBMITTER: Thuluva S 

PROVIDER: S-EPMC11964491 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature